Business
Antibody IP transfer agreement
Fusion Antibodies plc has entered into an Intellectual Property Transfer Agreement with Finn Therapeutics Ltd, a client, for a novel rabbit antibody, receiving a one-off payment of £250,000. This payment, which will be recognized in the current financial year ending March 31, 2026, is for the IP and related reach through to humanized sequences. The agreement includes tailored payment terms to support the client's fundraising activities, and Finn Therapeutics intends to continue its projects with Fusion as the humanized antibody development progresses. Disclaimer*
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n30 March 2026\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nAntibody IP transfer agreement\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has entered into an agreement to transfer the ownership of certain background intellectual property (\"IP\") owned by Fusion (the \"IP Transfer Agreement\") to an existing client, Finn Therapeutics Ltd (the \"Client\"). The IP Transfer Agreement covers a novel rabbit antibody.\n \nThe IP Transfer Agreement results in a one-off payment to Fusion of £250,000 for the IP and related reach through to the humanized sequences. The Client is pleased to take ownership of the background IP as this is expected to streamline its fundraising activities and the Company has agreed to tailored payment terms with the Client to allow for these fundraising activities.\n \nThe Client has been working closely with Fusion, placing a series of projects with the Company and has indicated it intends to continue to do so as the development of the humanised antibody progresses. The entire IP Transfer Agreement fee payable to Fusion will be recognised in the current financial year ending 31 March 2026.\n \nAdrian Kinkaid, CEO of Fusion, said: \"We are delighted with the progress that has been made with this molecule and its derivatives. We recognise the challenging investment conditions many small biotechnology companies face at this time and are keen to support our clients with creative deal solutions such as this. We look forward to working with Finn Therapeutics as they progress this project and bring better antibodies to the clinic more rapidly. The project highlights the strong reputation that Fusion has as the collaborative research partner of choice for antibody therapeutics.\"\n \nPaul Kerr, CEO of Finn Therapeutics commented: \"Acquiring full ownership of this backgro...